Early, but not late, treatment with human umbilical cord blood-derived mesenchymal stem cells attenuates cisplatin nephrotoxicity through immunomodulation.

@article{Park2017EarlyBN,
  title={Early, but not late, treatment with human umbilical cord blood-derived mesenchymal stem cells attenuates cisplatin nephrotoxicity through immunomodulation.},
  author={Ji Hyeon Park and Hye Ryoun Jang and Do Hee Kim and Ghee Young Kwon and Jung Eun Lee and Wooseong Huh and Soo Jin Choi and Wonil Oh and Ha Oh and Y G Kim},
  journal={American journal of physiology. Renal physiology},
  year={2017},
  volume={313 4},
  pages={F984-F996}
}
Preemptive treatment with mesenchymal stem cells (MSCs) can attenuate cisplatin-induced acute kidney injury (AKI). However, it is uncertain whether MSC treatment after the development of renal dysfunction prevents AKI progression or if MSC immunomodulatory properties contribute to MSC therapy. In this study, human umbilical cord blood (hUCB)-derived MSCs were used to compare the effects and mechanisms of early and late MSC therapy in a murine model. After cisplatin injection into C57BL/6 mice… CONTINUE READING

Similar Papers

Loading similar papers…